Shonni J Silverberg1, Bart L Clarke, Munro Peacock, Francisco Bandeira, Stephanie Boutroy, Natalie E Cusano, David Dempster, E Michael Lewiecki, Jian-Min Liu, Salvatore Minisola, Lars Rejnmark, Barbara C Silva, Marcella D Walker, John P Bilezikian. 1. Columbia University College of Physicians & Surgeons (S.J.S., N.E.C., D.D., M.D.W., J.P.B.) New York, New York 10032; Mayo Clinic (B.L.C.), Rochester, Minnesota 55902; Indiana University School of Medicine (M.P.), Indianapolis, Indiana 46202; University of Pernambuco School of Medicine (F.B.), 52050-450 Recife, Brazil; INSERM UMR 1033, Université de Lyon (S.B.), 69437 Lyon, France; New Mexico Clinical Research and Osteoporosis Center (E.M.L.), University of New Mexico School of Medicine, Albuquerque, New Mexico 87106; Shanghai Jiao-tong University School of Medicine (L.J.-M.), Shanghai 200025, People's Republic of China; Sapienza University of Rome (S.M.), 00161 Rome, Italy; Aarhus University Hospital (L.R.), 8000 Aarhus, Denmark; and Federal University of Minas Gerais (B.C.S.), Belo Horizonte 30.130-100, Brazil.
Abstract
OBJECTIVE: This report summarizes data on traditional and nontraditional manifestations of primary hyperparathyroidism (PHPT) that have been published since the last International Workshop on PHPT. PARTICIPANTS: This subgroup was constituted by the Steering Committee to address key questions related to the presentation of PHPT. Consensus was established at a closed meeting of the Expert Panel that followed. EVIDENCE: Data from the 5-year period between 2008 and 2013 were presented and discussed to determine whether they support changes in recommendations for surgery or nonsurgical follow-up. CONSENSUS PROCESS: Questions were developed by the International Task Force on PHPT. A comprehensive literature search for relevant studies was undertaken. After extensive review and discussion, the subgroup came to agreement on what changes in the recommendations for surgery or nonsurgical follow-up of asymptomatic PHPT should be made to the Expert Panel. CONCLUSIONS: 1) There are limited new data available on the natural history of asymptomatic PHPT. Although recognition of normocalcemic PHPT (normal serum calcium with elevated PTH concentrations; no secondary cause for hyperparathyroidism) is increasing, data on the clinical presentation and natural history of this phenotype are limited. 2) Although there are geographic differences in the predominant phenotypes of PHPT (symptomatic, asymptomatic, normocalcemic), they do not justify geography-specific management guidelines. 3) Recent data using newer, higher resolution imaging and analytic methods have revealed that in asymptomatic PHPT, both trabecular bone and cortical bone are affected. 4) Clinically silent nephrolithiasis and nephrocalcinosis can be detected by renal imaging and should be listed as a new criterion for surgery. 5) Current data do not support a cardiovascular evaluation or surgery for the purpose of improving cardiovascular markers, anatomical or functional abnormalities. 6) Some patients with mild PHPT have neuropsychological complaints and cognitive abnormalities, and some of these patients may benefit from surgical intervention. However, it is not possible at this time to predict which patients with neuropsychological complaints or cognitive issues will improve after successful parathyroid surgery.
OBJECTIVE: This report summarizes data on traditional and nontraditional manifestations of primary hyperparathyroidism (PHPT) that have been published since the last International Workshop on PHPT. PARTICIPANTS: This subgroup was constituted by the Steering Committee to address key questions related to the presentation of PHPT. Consensus was established at a closed meeting of the Expert Panel that followed. EVIDENCE: Data from the 5-year period between 2008 and 2013 were presented and discussed to determine whether they support changes in recommendations for surgery or nonsurgical follow-up. CONSENSUS PROCESS: Questions were developed by the International Task Force on PHPT. A comprehensive literature search for relevant studies was undertaken. After extensive review and discussion, the subgroup came to agreement on what changes in the recommendations for surgery or nonsurgical follow-up of asymptomatic PHPT should be made to the Expert Panel. CONCLUSIONS: 1) There are limited new data available on the natural history of asymptomatic PHPT. Although recognition of normocalcemic PHPT (normal serum calcium with elevated PTH concentrations; no secondary cause for hyperparathyroidism) is increasing, data on the clinical presentation and natural history of this phenotype are limited. 2) Although there are geographic differences in the predominant phenotypes of PHPT (symptomatic, asymptomatic, normocalcemic), they do not justify geography-specific management guidelines. 3) Recent data using newer, higher resolution imaging and analytic methods have revealed that in asymptomatic PHPT, both trabecular bone and cortical bone are affected. 4) Clinically silent nephrolithiasis and nephrocalcinosis can be detected by renal imaging and should be listed as a new criterion for surgery. 5) Current data do not support a cardiovascular evaluation or surgery for the purpose of improving cardiovascular markers, anatomical or functional abnormalities. 6) Some patients with mild PHPT have neuropsychological complaints and cognitive abnormalities, and some of these patients may benefit from surgical intervention. However, it is not possible at this time to predict which patients with neuropsychological complaints or cognitive issues will improve after successful parathyroid surgery.
Authors: Rachel P Espiritu; Ann E Kearns; Kristin S Vickers; Clive Grant; Euijung Ryu; Robert A Wermers Journal: J Clin Endocrinol Metab Date: 2011-09-14 Impact factor: 5.958
Authors: F De Lucia; S Minisola; E Romagnoli; J Pepe; C Cipriani; A Scillitani; N Parikh; D S Rao Journal: J Endocrinol Invest Date: 2012-06-18 Impact factor: 4.256
Authors: Ego Seeman; Pierre D Delmas; David A Hanley; Deborah Sellmeyer; Angela M Cheung; Elizabeth Shane; Ann Kearns; Thierry Thomas; Steven K Boyd; Stephanie Boutroy; Cesar Bogado; Sharmila Majumdar; Michelle Fan; Cesar Libanati; Jose Zanchetta Journal: J Bone Miner Res Date: 2010-08 Impact factor: 6.741
Authors: Barbara Campolina Silva; Stephanie Boutroy; Chiyuan Zhang; Donald Jay McMahon; Bin Zhou; Ji Wang; Julia Udesky; Serge Cremers; Marta Sarquis; Xiang-Dong Edward Guo; Didier Hans; John Paul Bilezikian Journal: J Clin Endocrinol Metab Date: 2013-03-22 Impact factor: 5.958
Authors: Jesús Villar-Del-Moral; João Capela-Costa; Antonio Jiménez-García; Antonio Sitges-Serra; Daniel Casanova-Rituerto; José Rocha; Juan Manuel Martos-Martínez; Aitor de la Quintana-Basarrate; Jorge Rosa-Santos; Xavier Guirao-Garriga; José Miguel Bravo-de-Lifante; Óscar Vidal-Pérez; Antonio Moral-Duarte; José Polónia Journal: Langenbecks Arch Surg Date: 2015-12-19 Impact factor: 3.445
Authors: F Saponaro; F Cetani; L Mazoni; M Apicella; M Di Giulio; F Carlucci; M Scalese; E Pardi; S Borsari; J P Bilezikian; C Marcocci Journal: J Endocrinol Invest Date: 2019-12-23 Impact factor: 4.256
Authors: B Sacconi; R Argirò; Daniele Diacinti; A Iannarelli; M Bezzi; C Cipriani; D Pisani; V Cipolla; C De Felice; S Minisola; C Catalano Journal: Eur Radiol Date: 2015-05-31 Impact factor: 5.315
Authors: C Marcocci; M L Brandi; A Scillitani; S Corbetta; A Faggiano; L Gianotti; S Migliaccio; S Minisola Journal: J Endocrinol Invest Date: 2015-03-28 Impact factor: 4.256
Authors: Claudiu Eduard Nistor; Camelia Stanciu-Găvan; Florina Vasilescu; Adrian Vasile Dumitru; Adrian Ciuche Journal: Exp Ther Med Date: 2021-07-07 Impact factor: 2.447